Preliminary unaudited Q4 and Full Year 2025 net Attruby®product revenue of $146.0 million and $362.4 million, respectively ...

Angela Ryan Lee, MD, FACC, is a board-certified cardiology and internal medicine physician. She also holds board certifications from the American Society of Nuclear Cardiology and the National Board ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

Google has made a change to how it’s search results are served which will also help to secure it against bots and scrapers. Whether this will have further effect on SEO Tools or if they can use a ...

ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

Alnylam’s closely watched launch of its rare disease drug Amvuttra continued to outpace Wall Street expectations. Riding its March expansion into the heart condition of transthyretin amyloid ...

Based on Nobel Prize-winning CRISPR/Cas9 gene editing technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate ...

The life expectancy for transthyretin (ATTR) amyloidosis varies from person to person. Your age, overall health, and primary symptoms all play a role. Transthyretin amyloidosis (ATTR) is a rare ...

As transthyretin amyloid cardiomyopathy (ATTR-CM) progresses, it can cause more serious problems with the heart and other parts of the body. Talking with your doctor about how the condition may ...

JavaScript’s low bar to entry has resulted in one of the richest programming language ecosystems in the world. This month’s report celebrates the bounty, while also highlighting a recent example of ...

Scoring tools validated to identify people at high risk of having transthyretin amyloid cardiomyopathy (ATTR-CM) still leave room for improvement in diverse populations. The ATTR-CM score and the ...

Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer will ...